DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $38.25.

A number of equities research analysts recently weighed in on the company. Guggenheim reissued a “buy” rating and set a $51.00 target price (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Citizens Jmp lifted their price objective on DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on DBV Technologies in a research report on Thursday, December 18th. Finally, Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th.

Insiders Place Their Bets

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the sale, the insider owned 7,303,369 shares of the company’s stock, valued at $30,601,116.11. The trade was a 15.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 3,369,627 shares of company stock worth $15,489,908 in the last 90 days. 1.44% of the stock is owned by insiders.

Institutional Trading of DBV Technologies

Several institutional investors have recently made changes to their positions in DBVT. Ikarian Capital LLC bought a new stake in DBV Technologies in the fourth quarter valued at about $10,064,000. Vestal Point Capital LP acquired a new position in DBV Technologies in the fourth quarter worth about $5,751,000. Squadron Capital Management LLC bought a new position in DBV Technologies during the fourth quarter worth about $4,601,000. Millennium Management LLC lifted its stake in DBV Technologies by 89.7% during the fourth quarter. Millennium Management LLC now owns 640,885 shares of the company’s stock worth $12,286,000 after purchasing an additional 303,022 shares during the period. Finally, Engineers Gate Manager LP acquired a new stake in DBV Technologies during the fourth quarter valued at approximately $479,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Stock Performance

NASDAQ:DBVT opened at $23.54 on Wednesday. The firm’s 50-day moving average is $21.08 and its 200-day moving average is $16.36. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -4.55 and a beta of -0.97. DBV Technologies has a 52-week low of $3.91 and a 52-week high of $26.18.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.